Ebola Updates Could Spark Hemispherx Biopharma (HEB) Stock

HEBWith ebola now having been diagnosed within the continental U.S., investors have been scrambling to find stocks that focus on finding some form of cure or treatment against the deadly disease. One NYSE-Amex listed penny stock, Hemispherx Biopharma, Inc. (HEB), has seen a flurry of traders flocking towards the specialty biopharmaceutical firm in hopes of being able to catch a ride on the hype-train for a chance to see some better days as the month of October progresses. Having been flipping around 0.30 and 0.37 for the better part of a month, HEB stock could be “the one” which offers the cheapest share price to go along with the biggest possible ROI as news continues to hit national media outlets.

Coming SoonWant to crush the Markets and make profits of $624, $2,897, even $40,656?
Click
HERE To Make Sure You Don’t Miss Our Penny Stock Alerts!

HEB Stock Quote

Market Cap: 70.20M
Last: 0.37 ▲ +0.05 (+15.63%)
Volume: 8,981,976
Dollar Volume: $
Open: 0.37
High: 0.38
Low: 0.34
Trades: 8,987
14-Day RSI: 67.46%
1st Resistance Point: 0.3927
1st Support Level: 0.3527
52Wk High: 0.66
52Wk Low: 0.18

On Monday, Hemispherx Biopharma made it known to all that they were broadening their research collaborations designed to develop therapeutic cocktails against Ebola which may potentially overcome the emergence of drug resistance due to Ebola virus mutation. This news was received well by investors just one day prior to the Centers for Disease Control and Prevention confirming the first case of Ebola diagnosed on American soil in a press conference on Tuesday.

Hemispherx Biopharma could be a big player in the quest to find a cure/treatment/prevention for the ebola virus as they work effortlessly out of their 43,000 sq. ft. FDA approved facility in New Brunswick, NJ. With the virus having popped up from Liberia, the Company already has a strong hand in the region after having, on June 25, 2014, concluded strategic discussions in Johannesburg with Bioclones (Pty) Ltd., a leading South African biotechnology company, with three principle goals; 1) initiating studies utilizing Ampligen® as a potential adjuvant enhancement of Bioclones’ therapeutic cancer vaccine, currently in clinical trials in Cape Town, including pre-clinical studies followed, potentially, by a Phase 1 clinical trial; 2) seeking South African Medicine’s Control Council approval to conduct trials using Alferon® to eradicate the HIV virus in patients highly responsive to anti-retroviral therapy; and 3) initiating a joint effort to obtain commercial registration of both Ampligen(R) and Alferon(R) in the South African markets.

Having seen how virus breakouts have forced stocks of companies that deal with their cures and treatments to run like banshees, HEB stock looks like its setting up for another big pop like was witnessed back at the start of September. On the 8th, the Company announced that they and USAMRIID scientists agreed to test Alferon®, the only multi-species, natural alpha interferon commercially approved in the U.S. and Ampligen®, an experimental drug, to be evaluated against the deadly Ebola virus and HEB stock popped up from high 20’s where it had been teetering to the high 30’s as quickly as you can say “injection.”

Other than HEB, other big name players in the ebola game are:

  • Tekmira Pharmaceuticals Corp (TKMR)
    Sarepta Therapeutics, Inc. (SRPT)
    BioCryst Pharmaceuticals, Inc. (BCRX)
    Lakeland Industries Inc. (LAKE)
    Ocean Bio-Chem Inc. (OBCI)
    NanoViricides, Inc. (NNVC)
    Vical Incorporated (VICL)

With a potential upside of more than 80% heading towards the 52wk high of 0.66, HEB should be on everyone’s watchlist, especially if the OTC Markets wet the bed and defecate at the open like it did yesterday.

Looking for the Best Penny Stocks to Buy?
Click
HERE To Receive FREE Penny Stock Alerts

hot penny stocks, hot OTC stocks, best OTC stocks, best penny stocks

About HEB Stock

Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries, BioPro Corp., BioAegean Corp. and Core Biotech Corp., is a specialty pharmaceutical company engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

Click here to view the SEC filings for HEB.
Click here to view the website for Hemispherx Biopharma.

Authorized: 350,000,000
Issued and Outstanding: 189,997,547

Last 5 Trading Sessions:

Date Open High Low Last Change % Chg Volume
10/01/14 0.37 0.38 0.34 0.37 +0.05 +15.63% 8,973,200
09/30/14 0.32 0.32 0.30 0.32 unch unch 2,254,700
09/29/14 0.32 0.34 0.31 0.32 +0.02 +6.67% 1,057,600
09/26/14 0.30 0.32 0.30 0.30 -0.01 -3.23% 408,800
09/25/14 0.32 0.32 0.29 0.31 -0.01 -3.12% 940,300

 

facebookTwitterStay Connected With Us: 

Subscribe Footer

(We are 100% Anti-Spam and will never rent or sell your information) Although many of our picks go up 100, 200% even 4,000%, there is always the chance a stock could move lower.

Please read and understand our rules very carefully:

1. Penny Stocks can be very dangerous, unless you understand the risk involved with them do not try to trade them. Many go up fast and can drop just as fast;
2. Do not risk too much in one company. You can lose it all very quickly;
3. Do not “marry” any one stock. Recognize if you are wrong about a stock, cut your losses and move on to the next stock; and
4. Always use stop loss orders. We recommend that you use “trailing stops” in order to protect your profits.

Last updated by at .

0
  Recent Penny Stock News